18,090 Shares in TransMedics Group, Inc. $TMDX Acquired by Penserra Capital Management LLC

Penserra Capital Management LLC acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 18,090 shares of the company’s stock, valued at approximately $2,424,000. Penserra Capital Management LLC owned 0.05% of TransMedics Group as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of TMDX. Opal Wealth Advisors LLC bought a new stake in shares of TransMedics Group during the second quarter worth $26,000. Smartleaf Asset Management LLC grew its holdings in shares of TransMedics Group by 44.3% in the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock worth $30,000 after purchasing an additional 135 shares during the last quarter. Quarry LP increased its stake in TransMedics Group by 88.5% in the 1st quarter. Quarry LP now owns 592 shares of the company’s stock worth $40,000 after buying an additional 278 shares during the period. Sound Income Strategies LLC bought a new stake in TransMedics Group during the 2nd quarter valued at about $48,000. Finally, Hager Investment Management Services LLC lifted its holdings in TransMedics Group by 38.3% during the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company’s stock valued at $50,000 after buying an additional 205 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on TMDX shares. Morgan Stanley upped their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a research note on Friday, August 1st. Jefferies Financial Group started coverage on TransMedics Group in a report on Monday, October 13th. They issued a “buy” rating and a $145.00 price target for the company. Stifel Nicolaus started coverage on TransMedics Group in a research note on Thursday, September 4th. They issued a “hold” rating and a $115.00 price objective on the stock. Piper Sandler reduced their price objective on TransMedics Group from $145.00 to $140.00 and set an “overweight” rating on the stock in a report on Thursday, October 30th. Finally, Canaccord Genuity Group lifted their target price on TransMedics Group from $142.00 to $147.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, TransMedics Group has an average rating of “Moderate Buy” and an average target price of $130.73.

TransMedics Group Price Performance

NASDAQ TMDX opened at $119.17 on Monday. The company has a market cap of $4.07 billion, a PE ratio of 48.25 and a beta of 2.05. The firm’s 50 day moving average price is $117.77 and its 200-day moving average price is $119.05. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $145.50.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. The company had revenue of $143.82 million during the quarter, compared to the consensus estimate of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. TransMedics Group’s revenue for the quarter was up 32.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.12 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. Sell-side analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Activity at TransMedics Group

In related news, Director Edward M. Basile sold 4,142 shares of the company’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $130.45, for a total transaction of $540,323.90. Following the completion of the sale, the director directly owned 2,866 shares in the company, valued at $373,869.70. This represents a 59.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders own 7.00% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.